Blue Horseshoe Stocks: HIRU, OWCP Recaps & More

Hiru Corp. HIRU

Yesterday we re-signaled HIRU, a stock we’ve mentioned a couple times in 2017 already, beginning with our very first report of the year, subsequent to which we would observe a low of .0011.

So far this week, the stock has really picked up the pace with two consecutive bullish sessions. Yesterday alone it traded in a range from .0021 to a new high of .0036 just prior to the close, putting in a 71% intraday move. From our observed low, it marks an overall upswing of 227%, not to mention the fact that it closed just a single tick below that high of day at .0035.

Such a performance definitely warrants continued observation on HIRU in sessions to come.

OWC Pharmaceutical Research Corp. OWCP

Speaking of late-day pushes, we got one out of OWCP yesterday, which ran from a morning low of .21 up to .2957. That is the highest we’ve seen it yet since our next most recent report on the stock which came in mid-November.  Following that, we would catch OWCP trading as low as .085. That means, at yesterday’s new top mark, we had witnessed an overall upswing of 248% in less than two months.

If we jump back slightly further to our report dated 09/29, you can see that we actually caught this one at the subpenny level (.0045) from which yesterday’s new high represented an earth-shattering 6471% (<–That is not a typo!)

Granted the fact that yesterday’s high was its highest recorded PPS since 2014, we’d have to designate this one as a blue sky breakout, and continue to stay on its trail. Like any rapid riser, awareness of a possible dip-and-rip at some point must be maintained as well.

Biocept, Inc. BIOC

We’re also going to want to keep tabs on BIOC after yesterday monumental move on the strength of an agreement the company struck with Blue Cross & Blue Shield of Texas (>>Read PR). It’s a potentially lucrative development, and that is really showing through with the resulting activity on the chart.

With the stock having shattered previous resistance yesterday, we’re going to be monitoring for a continuation of the terrific momentum buildup from yesterday, as well as the possibility for a subsequent dip-and-rip pattern that could provide us with healthy opportunities over the course of the next few days.

Extended Watchlist:

Blue Horseshoe Stocks: GIGL Review, Other Updates

Giggles N’ Hugs, Inc. GIGL

We’ve been hot on GIGL’s trail since tagging it in Friday’s premarket report, after catching it come off of a bottom. As of the end of that session, we’d witnessed a move of more than 350% from our observed low of .0053, to a high of .024, which occurred on record volume.

Yesterday we reminded our members to continue to keep tabs on the stock, and heeding that suggestion would have extended gain opportunities significantly with the daily performance that followed. GIGL managed to achieve a new high, trading up 140% intraday from .02 to .048. That new high mark represented a two-session swing of 806%

With the stock closing strongly at .035, we will of course be continuing to monitor its activity as we progress through the week.

Accelera Innovations, Inc. ACNV

We also tagged ACNV in yesterday’s morning report, and were pleased with the magnitude of the possible gains that were available there. The stock traded in a range from .008 and managed to hit .015.

That was the second subpenny play in as many days to crack the penny barrier on our watch (GIGL being the other), and it was good for intraday gains of up to 88% A strong close on healthy volume warrants further tracking in this instance as well.

Eli Lilly & Co. LLY – Options Update

On the 16th of last month, we formulated an extended-term options idea for LLY, and this morning, we’d like to take a second to update our readers on the level of gains that call has attained in recent weeks.

Our specific target contracts were the LLY 01/20 $75 Calls and the move we have observed in those has been quite good. A run from a low of .75 to as much as 2.50, which works out to total possible gains of up to 233%

Mountain High Acquisitions Corp. MYHI

We’ve got one last update this morning for MYHI. Last Wednesday, we tagged this stock, along with a varied group of several legal and medical marijuana plays, and just wanted to circle back to go over the fact that it has followed our expectations to the letter.

After the huge initial move we witnessed from .09-.239 (+166%) that first day, we followed up with an added caution, explicitly stating that “we expect a consolidation that should lead to a dip-and-rip pattern”.

That is exactly what has come to pass, as MYHI consolidated back to a low of .0909, before launching back to .175 yesterday. The move afforded us a chance to realize further gains to the tune of 93% on the rebound.

Along with MYHI, we’ll continue to watch several cannabis stocks, which comprise the vast majority of today’s extended watchlist.

Extended Watchlist:

Blue Horseshoe Stocks: LXRP News Update & FDA-Related Plays

Lexaria Corp. LXRP

Following our initial report on LXRP yesterday, the stock had a productive session as it traded in a range from .095 to a high of .108, an intraday gain of 14% on roughly 2.5X the monthly average volume. It closed at .102 holding more than half of the day’s gains, which is generally a good sign.

We promised to relay any further updates regarding the current status of LXRP, and sure enough the company published a fresh PR this morning containing another major development. It relates to the sale of Lexaria’s domestic oil assets, which we mentioned in yesterday’s report, becoming final with all funds received. It provides LXRP with a cash infusion of $1.4M which will facilitate a clearing of all debt currently on the books, as well as advance the company’s plans to release a CBD-infused tea (infusion method is patent pending) via a new online sales portal. With the rate at which LXRP has been executing its strategies, we expect to hear about the opening of that website any day now.

KELOWNA, BC / ACCESSWIRE / December 10, 2014 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratulates the new owners for having purchased a fine asset. >> FULL PR

FDA-Related News

We caught a couple of FDA news plays on this morning’s scan that we’ll want to keep an eye on:

ARCA BioPharma, Inc. ABIO has reported that the FDA “has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.” >> VIEW PR

Cytori Therapeutics, Inc. CYTX announced that the FDA granted approval “for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.” >> VIEW PR

Extended Watchlist:

Blue Horseshoe Stocks: LXRP Special Report

Lexaria Corp. LXRP

It has been several weeks since we last zeroed in on a new interest in the cannabis sector, and this morning’s new topic of discussion, LXRP, falls under that category.

One of the main factors drawing us to this play is the total commitment the company has recently begun to show in focusing all its resources toward furthering its position in the marijuana space during a time when support for the allowance of medical marijuana in this country is at an all-time high. This includes the sale of domestic oil assets that will provide the funds to make the company debt-free for the first time since 2007, as well as continue to move forward with different opportunities involving cannabis and its beneficial chemical compounds.

There certainly are quite a few irons in the fire; the sheer number and content of recent press releases alone demonstrates LXRP‘s commitment to establishing itself as a player in both the Canadian medical marijuana market (through Health Canada’s MMPR program) and the U.S in places where marijuana and CBD-infused products are now legal. We’ll provide links to those announcements at the bottom of this report.

Lexaria began its shift toward cannabis back in March, when it teamed up with Enertopia Corp. (OTCQB:ENRT) in a joint venture that would go on to file an application with Heath Canada in July to produce 10,000kg of medical marijuana each year under the MMPR program. At $5/gram, those production levels could generate some $50 million per year in revenue of which Lexaria would be entitled to 49%. That application is still pending as the Canadian government sifts through the 1000-odd submissions it has received for medical marijuana producer licenses.

The venture with Enertopia, combined with another one struck with Huntington Property Group this spring, when all is said and done, could provide up to 140,000 square feet of growing space. According to some current producers figures, each square foot has the potential to yield up to $1000/year in revenue.

In addition to its joint ventures pertaining to grow operations, in November LXRP acquired 51% of PoViva Corp., which is where the CBD-infused products come in. According to the corresponding PR, “PoViva owns two patents pending that govern the process used to infuse the CBD into food products, and both patents pending are part of the acquisition.” For those who may be unfamiliar, CBD (Cannabidiol) is one of the 85 cannabinoid compounds found in the cannabis plant, and according to a growing number of studies, has a number of legitimately beneficial medical uses.

Something else that alerting us to the potential of LXRP is the tight share structure; a low float play like this one can move up on a puff of air, and has the potential to very quickly turn into the type of rapid mover that we’re constantly trying to track down.

With regard to the chart itself, the stock has been trending off of a bottom for the past several weeks, and for the first time in months, LXRP has breached and closed above its 20DMA. It appears key resistance is set up at the recent swing high of .11, and if LXRP can break that point, the next areas of resistance crop up at the 200DMA and 50DMA of .172 and .18 respectively. A return to those levels from the current price would mean triple-digit gains for LXRP so we’ll definitely have this one on our radars going forward.

This morning, we got a news update on LXRP‘s growers license application, with the company signifying that it has passed the preliminary screening phase, and is underway with the advanced screening phase >>> READ PR


Get More Info on LXRP @